Biotech News
-
Voyageur Pharmaceuticals Ltd. Announces Resignation of CFO and Appointment of Interim CFO and Shares for Debt Transaction
August 15, 2022 (Source) – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) has appointed Albert Deslauriers as…
-
Awakn Life Sciences Expands Commercial Operations into the U.S. – First Licensing Partnership Agreement with Revitalist
Awakn enters the U.S. addiction treatment and relapse prevention market August 15, 2022 (Source) – Awakn Life Sciences Corp.…
-
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
August 12, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) announces that it has closed a…
-
Sixth Wave Innovations Inc. and Magnus Mineral Resources (PVT) Ltd Sign Memorandum of Understanding for Testing IXOS(R) Mining Technology and Implementation at the Penhalonga Gold Mine
August 9, 2022 (Source) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave or SIXW or…
-
Zentek Provides Update on Commercial Partnerships
August 5, 2022 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and…
-
SIXW: Correction of News Release
August 2, 2022 (Source) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or the…
-
Valeo Pharma Closes US$40 Million Non-Dilutive Financing from Sagard Healthcare Partners
Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand…
-
Valeo Pharma Enters into License Agreement with Kaléo for the Canadian Rights to ALLERJECT®
700,000 Canadians suffering from severe allergies Canadian epinephrine auto-injector market exceeds $80M annually ALLERJECT peak sales potential expected to…
-
Valeo Pharma Enters into an Agreement for Ophthalmic Products, PrXIIDRA® AND PrSIMBRINZA®, in Canada
Ophthalmology becomes additional strategic therapeutic area Significant market opportunities with more than 6 million1 Canadians suffering from dry eye…
-
Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
Phase III Trial to Cost approximately CA$3.75 million with Awakn’s contribution expected to be approximately CA$1.25 million, Marks…
